Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database
Samin Mohsenian,Roberta Palla,Marzia Menegatti,Andrea Cairo,Anna Lecchi,Alessandro Casini,Marguerite Neerman-Arbez,Rosanna Asselta,Sara Scardo,Simona Maria Siboni,Jan Blatny,Ondrej Zapletal,Jean-Francois Schved,Muriel Giansily-Blaizot,Susan Halimeh,Mohamad Ayman Daoud,Helen Platokouki,Helen Pergantou,Roger E G Schutgens,Monique Van Haaften-Spoor,Paul Brons,Britta Laros-van Gorkom,Elise Van Pinxten,Munira Borhany,Naveena Fatima,Danijela Mikovic,Marko Saracevic,Gül Nihal Özdemir,Yılmaz Ay,Michael Makris,Caryl Lockley,Andrew Mumford,Andrew Harvey,Steve Austin,Amy Shapiro,Adrianna Williamson,Catherine McGuinn,Ilene Goldberg,Philippe De Moerloose,Flora Peyvandi,Jan Blatný,Ayman Daoud,Roger E.G. Schutgens,Britta A.P. Laros-van Gorkom,Andrew D. Mumford,Steven Kenneth Austin,Amy D. Shapiro,Philippe de Moerloose
DOI: https://doi.org/10.1182/bloodadvances.2023012186
IF: 7.642
2024-01-29
Blood Advances
Abstract:Congenital fibrinogen deficiency (CFD) is a rare bleeding disorder caused by mutations in FGA, FGB and FGG. We sought to comprehensively characterize patients with CFD using PRO-RBDD (Prospective Rare Bleeding Disorders Database). Clinical phenotypes, laboratory and genetic features were investigated using retrospective data from the PRO-RBDD. Patients were classified from asymptomatic to grade III based on their bleeding severity. In addition, FGA, FGB and FGG were sequenced to find causative variants. A total of 166 CFD cases from 16 countries were included, of whom 123 (30 afibrinogenemia, 33 hypofibrinogenemia, 55 dysfibrinogenemia, 5 hypodysfibrinogenemia) were well characterized. Considering the previously established factor activity and antigen level thresholds, bleeding severity was correctly identified in 58% of cases. The rate of thrombotic events among afibrinogenemic and hypofibrinogenemic patients were relatively similar (11% and 10%) and surprisingly higher than in dysfibrinogenemic cases. The rate of spontaneous abortions among 68 pregnancies was 31%, including 86% in dysfibrinogenemic women and 14% with hypofibrinogenemia. 86 patients received treatment (69 on-demand and/or 17 on prophylaxis), fibrinogen concentrates being the most frequently used product. Genetic analysis was available for 91 cases and 41 distinct variants were identified. Hotspot variants (FGG, p.Arg301Cys/His and FGA, p.Arg35Cys/His) were present in 51% of dysfibrinogenemia. Obstetric complications were commonly observed in dysfibrinogenemia. This large multicenter study provided a comprehensive insight into the clinical, laboratory and genetics of patients with CFDs. We conclude that bleeding severity grades were in agreement with the established factor activity threshold in nearly half of the cases with quantitative defects.
hematology